D. E. Shaw & Co., Inc. Kronos Bio, Inc. Transaction History

D. E. Shaw & Co., Inc.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$0.75 - $1.49 $86,835 - $172,512	-115,780 Reduced 31.23%	254,987 $318,000
Q3 2023 Nov 14, 2023	BUY	$1.23 - $2.25 $1,093 - $2,000	889 Added 0.24%	370,767 $481,000
Q2 2023 Aug 14, 2023	BUY	$1.24 - $1.92 $66,224 - $102,541	53,407 Added 16.88%	369,878 $636,000
Q1 2023 May 15, 2023	SELL	$1.34 - $2.62 $46,957 - $91,812	-35,043 Reduced 9.97%	316,471 $462,000
Q4 2022 Feb 14, 2023	BUY	$1.44 - $3.44 $62,160 - $148,494	43,167 Added 14.0%	351,514 $569,000
Q3 2022 Nov 14, 2022	BUY	$3.35 - $5.55 $68,524 - $113,525	20,455 Added 7.11%	308,347 $1.03 Million
Q2 2022 Aug 15, 2022	BUY	$3.12 - $7.52 $898,223 - $2.16 Million	287,892 New	287,892 $1.05 Million
Q1 2021 May 17, 2021	SELL	$27.0 - $32.48 $324,729 - $390,636	-12,027 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$26.68 - $38.23 $320,880 - $459,792	12,027 New	12,027 $359,000

19.8M

9.3K

100

Ticker KRON
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,769,100
Market Cap $53.9M
Description
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally...

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.